A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation

04/10/2024
14/02/2025
EU PAS number:
EUPAS1000000327
Study
Planned
Documents
Study protocol
Initial protocol
English (3.5 MB - PDF) View document
Study results
Study report
Other information